GlassScriptPhysician profile
Kristen Master
NPI 1427590819
$1,530.50
in general payments reported to CMS, 2019-2025
33 companies · $1,087 in 2025
The $1,087 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.72 · 2022: $28.88 · 2023: $20.93 · 2024: $373 · 2025: $1,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,382 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,381.90 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $139.51 | 2024-2025 | Enhertu, Injectafer, Datroway |
| Tersera Therapeutics LLC | $125.67 | 2025 | Zoladex, Xermelo |
| Aveo Pharmaceuticals, INC. | $118.33 | 2025 | |
| Novartis Pharmaceuticals Corporation | $110.45 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $102.20 | 2021-2025 | Keytruda, Lynparza |
| Tempus Ai, INC | $100.00 | 2024 | |
| Genzyme Corporation | $70.23 | 2024-2025 | |
| Servier Pharmaceuticals LLC | $53.84 | 2024-2025 | |
| Abbvie INC. | $50.09 | 2025 | |
| Janssen Biotech, INC. | $48.73 | 2025 | Rybrevant, Carvykti |
| Celgene Corporation | $47.55 | 2025 | Opdivo |
| Lilly USA, LLC | $46.25 | 2024-2025 | |
| Incyte Corporation | $42.83 | 2024-2025 | Monjuvi, Jakafi |
| Menarini Silicon Biosystems, INC. | $41.36 | 2025 | |
| Emd Serono, INC. | $39.71 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $39.24 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $34.25 | 2022-2025 | |
| Syndax Pharmaceuticals, INC. | $26.78 | 2025 | |
| Jazz Pharmaceuticals INC. | $26.70 | 2025 | |
| Geron Corporation | $25.45 | 2025 | Rytelo |
| Eisai INC. | $23.27 | 2025 | |
| Adaptive Biotechnologies Corporation | $20.69 | 2024 | Clonoseq |
| Agios Pharmaceuticals, INC. | $19.91 | 2024 | Pyrukynd |
| Array Biopharma INC | $19.55 | 2024 | Braftovi, Mektovi |
| Beigene USA, INC. | $19.49 | 2024 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $19.17 | 2025 | Opdivo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.75 | 2025 | |
| Recordati_rare_diseases_inc. | $18.37 | 2025 | Sylvant |
| Deciphera Pharmaceuticals INC. | $17.97 | 2025 | |
| Glaxosmithkline, LLC. | $17.95 | 2025 | Zejula |
| Alnylam Pharmaceuticals INC. | $16.97 | 2025 | Givlaari |
| Exelixis INC. | $16.13 | 2024 | Cabometyx |
| Gilead Sciences, INC. | $13.11 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Master listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.